Español
India
Italiano
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dermata Therapeutics
(NASDAQ:DRMA)
Intraday
$3.50
-0.2187
[-5.88%]
After-Hours
$3.50
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$3.50
-0.2187
[-5.88%]
At close: Jun 6
$3.50
0
[0.00%]
After Hours: 6:57PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Dermata Therapeutics Stock (NASDAQ:DRMA)
Dermata Therapeutics Stock (NASDAQ: DRMA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, June 05, 2024
Dermata Therapeutics On June 4 Got Letter From Nasdaq That Company Has Regained Compliance With Minimum Bid Price Requirement
Benzinga Newsdesk
Tuesday, May 28, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
Friday, May 17, 2024
Dermata Therapeutics Entred Agreements For The Immediate Exercise Of Certain Warrants To Purchase Up To An Aggregate Of 516,336 Shares Of The Co's Common Stock, Having Exercise Prices Of $9.7665 And $32.40 Per Share
Benzinga Newsdesk
Wednesday, May 15, 2024
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk
Dermata Therapeutics Q1 2024 GAAP EPS $(0.47) Misses $(0.36) Estimate
Benzinga Newsdesk
Tuesday, May 14, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
Friday, May 10, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
Monday, April 22, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Tuesday, April 16, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
Thursday, March 21, 2024
Dermata Therapeutics FY23 EPS $(2.67) Vs $(13.92) YoY
Benzinga Newsdesk
Wednesday, January 17, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
Friday, January 05, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
Dow Turns Lower; ISM Services PMI Falls In December
Avi Kapoor
Why Is Aesthetic Skin Conditions-Focused Dermata Therapeutics Stock Trading Higher Today?
Vandana Singh
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Thursday, January 04, 2024
Dermata shares are trading higher after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis.
Benzinga Newsdesk
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
Dermata Announces Issuance Of Patent In Japan For DMT410 Program For Treatment Of Hyperhidrosis
Benzinga Newsdesk
Wednesday, December 20, 2023
Dermata Enrolls First Patient In Pivotal DMT310 Phase 3 STAR-1 Clinical Trial For Acne; About 550 Patients Will Be Treated Once Weekly For 12 Weeks
Benzinga Newsdesk
Thursday, December 14, 2023
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
Monday, November 20, 2023
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Thursday, November 16, 2023
Why Children's Place Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Crude Oil Down 4%; Walmart Shares Fall After Q3 Results
Lisa Levin
Dermata Therapeutics To Start Patient Enrollment In DMT310 Phase 3 STAR-1 Acne Clinical Program In December 2023 Based On Agreement With FDA On The Phase 3 Protocols; Topline Results Expected In Q1 2025
Benzinga Newsdesk
Thursday, November 09, 2023
Dermata Therapeutics Q3 EPS $(0.54) Beats $(0.63) Estimate
Benzinga Newsdesk
Monday, November 06, 2023
Top 5 Health Care Stocks That May Fall Off A Cliff This Month
Lisa Levin
Friday, November 03, 2023
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
Tuesday, October 31, 2023
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
Wednesday, August 30, 2023
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
Why REX American Resources Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
Why NanoVibronix Shares Are Trading Higher By 49%; Here Are 20 Stocks Moving Premarket
Lisa Levin
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
Thursday, August 10, 2023
Dermata Therapeutics Says Raises Aggregate Of $6.8M In Gross Proceeds From 2 Financings In H1 2023
Benzinga Newsdesk
Thursday, June 29, 2023
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
Tuesday, June 27, 2023
Dermata Therapeutics Announces FDA Feedback On The DMT310 Phase 3 Clinical Development Program In Moderate-To-Severe Acne
Benzinga Newsdesk
Thursday, June 08, 2023
Dermata Therapeutics Announces Results From Its DMT310 Phase 2b Acne Results Published In Journal Of The American Academy Of Dermatology
Benzinga Newsdesk
Wednesday, May 24, 2023
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
Dermata Therapeutics shares are trading lower after the company announced a $1.8 million offering of 800,877 shares of its common stock at a price of $2.285 per share.
Benzinga Newsdesk
Dermata Therapeutics Announces $1.8M Offering Of 800,877 Shares Of Common Stock At A Price Of $2.285/Share Priced At-The-Market Under Nasdaq Rules
Happy Mohamed
Monday, May 15, 2023
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Why NeoGames Shares Are Trading Higher By 121%; Here Are 20 Stocks Moving Premarket
Lisa Levin
Friday, May 12, 2023
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
Dow Turns Lower; Getaround Shares Jump
Lisa Levin
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch